

Title (en)
TRPV4 ANTAGONISTS

Title (de)
TRPV4-ANTAGONISTEN

Title (fr)
ANTAGONISTES DE TRPV4

Publication
EP 3515888 A1 20190731 (EN)

Application
EP 17784401 A 20170920

Priority
• US 201662397008 P 20160920
• US 201762482300 P 20170406
• IB 2017055702 W 20170920

Abstract (en)
[origin: WO2018055526A1] The present invention relates to pyrrolidine sulfonamide analogs (I), pharmaceutical compositions containing them and their use as TRPV4 antagonists.

IPC 8 full level
A61K 31/40 (2006.01); **A61K 31/41** (2006.01); **A61K 31/426** (2006.01); **A61K 31/4439** (2006.01); **A61P 1/16** (2006.01); **A61P 9/00** (2006.01); **A61P 11/00** (2006.01); **A61P 11/14** (2006.01); **A61P 13/10** (2006.01); **C07D 207/48** (2006.01); **C07D 401/12** (2006.01); **C07D 403/12** (2006.01); **C07D 417/12** (2006.01)

CPC (source: EP KR US)
A61K 31/40 (2013.01 - KR US); **A61K 31/41** (2013.01 - KR); **A61K 31/426** (2013.01 - KR); **A61K 31/427** (2013.01 - US); **A61K 31/4439** (2013.01 - KR US); **A61K 31/506** (2013.01 - US); **A61K 31/5386** (2013.01 - US); **A61K 45/06** (2013.01 - US); **A61P 1/04** (2017.12 - EP); **A61P 1/10** (2017.12 - EP); **A61P 1/14** (2017.12 - EP); **A61P 1/16** (2017.12 - EP KR); **A61P 1/18** (2017.12 - EP); **A61P 3/00** (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 7/10** (2017.12 - EP); **A61P 9/00** (2017.12 - EP KR); **A61P 9/04** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 9/12** (2017.12 - EP); **A61P 11/00** (2017.12 - EP KR); **A61P 11/02** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 11/14** (2017.12 - EP KR); **A61P 11/16** (2017.12 - EP); **A61P 13/10** (2017.12 - EP KR); **A61P 13/12** (2017.12 - EP); **A61P 15/00** (2017.12 - EP); **A61P 15/04** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/04** (2017.12 - EP); **A61P 19/00** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 21/02** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/06** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 27/02** (2017.12 - EP); **A61P 27/06** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/04** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 207/48** (2013.01 - EP KR US); **C07D 401/12** (2013.01 - EP KR US); **C07D 403/12** (2013.01 - EP KR US); **C07D 417/12** (2013.01 - EP KR US); **C07D 498/10** (2013.01 - US)

Citation (search report)
See references of WO 2018055526A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2018055526 A1 20180329; AU 2017330620 A1 20190328; BR 112019005416 A2 20190618; CA 3036933 A1 20180329; CN 109790116 A 20190521; CN 109790116 B 20221028; EP 3515888 A1 20190731; EP 3515888 B1 20210331; ES 2877763 T3 20211117; JP 2019532052 A 20191107; JP 7106528 B2 20220726; KR 20190049865 A 20190509; RU 2019110821 A 20201022; US 11260049 B2 20220301; US 2021299113 A1 20210930

DOCDB simple family (application)
IB 2017055702 W 20170920; AU 2017330620 A 20170920; BR 112019005416 A 20170920; CA 3036933 A 20170920; CN 201780057911 A 20170920; EP 17784401 A 20170920; ES 17784401 T 20170920; JP 2019515428 A 20170920; KR 20197010953 A 20170920; RU 2019110821 A 20170920; US 201716334400 A 20170920